Lumiliximab, also known as ST-152, represents a innovative antibody targeting the soluble ligand for IL-13. This molecule demonstrates notable potential in addressing inflammatory diseases , particularly those involving heart failure . Clinical trials indicate that the antibody efficiently neutralizes the activity of circulating IL-13, thereby dimi

Satralizumab, previously known as SA-237 , represents a promising therapy for neuromyelitis optica spectrum disorder and other autoimmune diseases . Recent clinical trials have indicated favorable results regarding its action in lessening relapses and disease burden. Notably, Phase III studies – including the ADAPT study – have assessed the im

New data suggests that Cilgavimab, formerly known as COV2-2130, demonstrates significant promise as a therapeutic agent against the coronavirus . This antibody exhibits a novel method of function, particularly targeting the pathogen's ACE2 receptor binding domain with considerable affinity . Early studies indicate a robust ability to block viral en